

“Kronikleşme Patogenezi”

Dr. Atahan Çağatay
İstanbul Tıp Fakóltesi
İnfeksiyon Hastalıkları
Ve Klinik Mikrobiyoloji Anabilim Dalı

Sunum Taslağı

- HBV ve HCV Kronikleşme Sıklığı
- Kronikleşme ve Hücre Ölümü
- HBV Kronikleşme Patogenezi
- HCV Kronikleşme Patogenezi

Kronikleşme Hızı

HBV

Çocuklarda

%90

Erişkinlerde

%5-10

HCV

Çocuklarda

%80-90

Erişkinlerde

%75-85

HDV


Çocuklarda

%2


Erişkinlerde

%90


Karaciğerde Hücre Ölüm Modelleri



Karaciğerde Hücre Ölüm Modelleri




Karaciğerde Hücre Ölüm Modelleri




Kronik Hepatit Seyri


HBV
HCV
HDV




Hepatoselüler
Karsinoma



Normal
Karaciğer




Kronik
Hepatit




Siroz


HCV İnfeksiyonunun Doğal Hikayesi



Fibroz Gelişiminde Ana Mekanizma




HBV ve HCV Kronik Süreci




HBV ve HCV Akut-Kronik Hepatit Seyri


a Hepatitis B (acute)




c Hepatitis C (acute)




b Hepatitis B (chronically evolving)



d Hepatitis C (chronically evolving)



HCV Molekülü



Hepatitis C virus RNA

9600 nt bases

Gene encoding precursor polypeptide

5' NTR

3' NTR

Structural proteins

non-structural proteins

p22

gp35

gp70

p7

p23

p70

p8

p27

p56/58

p68

C

E1

E2

NS1

NS2

NS3

NS4A

NS4B

NS5A

NS5B

Envelope
glycoproteins

nucleocapsid

proteases
RNA helicase


transmembrane
protein

co-factors


RNA polymerase

interferon
resisting
protein

HCV infeksiyonunun Doğal Seyri




HCV İnfeksiyonunun Seyri




HCV İnfeksiyonunun Seyri


b HCV life cycle




HCV ve Doğal İmmünite



“Stellate” Hücreleri ve Fibroz




Fibroz Gelişimi




HCV Patogenezi

Infeksiyon mu Hastalık mı?




HCV İnfeksiyonunun İmmünopatogenezi

HCV Antijenlerine Karşıt Hücre Aktivasyonu




HCV İnfeksiyonunun İmmünopatogenezi


CD4 T-Helper Hücrelerinin Dinamik Dengesi



HCV'nin İmmünite Aracılığı ile Temizlenmesi




HCV'nin İmmünite Aracılığı ile Temizlenmesi



HCV İnfeksiyonu

Karaciğer Fibrozunun Interferon- α ile inhibisyonu



Antifibrotik Mekanizmalar

↓ mRNA Ekspresyonu:

- TGF- β
- Prokollajen tip I
- Prokollajen III
- Prokollajen IV

↓ Serum Seviyeleri:

- Prokollajen tip III peptid
- Hyaluronik asit
- TIMP-1

– mRNA Ekspresyonu:


- Collagenase
- MMP

Kupffer Hücreleri ve HBV-HCV:


Kronikleşme


	HBV		HCV	
	Mediators	[Ref.]	Mediators	[Ref.]
Binding/uptake				
	HSPG	[79]	HSPG	[79]
	CD14	[9]	SR-B1	[82]
	mannose receptor	[69]	LDL-receptor	[81]
			DC-SIGN	[9, 85]
Pattern recognition receptors				
			TLR2	[84, 87]
			TLR4	[88]
Cytokines				
	IL-1 β	[89]	IL-1 β	[84, 100]
	IL-6	[89]	TNF	[84]
	TNF	[89]	IL-10	[84]
	TGF β	[91]		
Chemokines				
	CXCL8	[89]		
Co-stimulatory molecules				
			CD40	[94]
			CD80	[94]
			MHC class II	[94]
Immune inhibition or promotion of tolerance				
	TGF β	[91]	PD-L1	[84, 137]
	PD-L2	[30]	IL-10	[84]
	galectin-9	[135]	galectin-9	[120]
Liver damage				
	IL-6	[89]	TRAIL	[84]
	TRAIL	[84]	granzyme B	[105, 106]
	FasL	[106]	perforin	[105, 106]
	granzyme B	[105]		
	perforin	[105]		
	ROS	[54]		
	galectin-9	[135]		
	TGF β	[91]		

Kupffer Hücreleri ve HBV-HCV: Kronikleşme



Kupffer Hücreleri ve HBV-HCV: Kronikleşme







Points of intervention in the HCV life cycle

- ① The viral particle (neutralizing antibodies, virocidal peptides)
- ② Entry and receptor interaction (antibodies and small molecules targeting receptors, kinase inhibitors)
- ③ Translation and polyprotein processing (NS3-NS4A protease inhibitors)
- ④ HCV RNA replication (NS5B polymerase and NS5A inhibitors, miR-122 antagonists, cyclophilin inhibitors, statins, PI4KIII α inhibitors)
- ⑤ Assembly and virion morphogenesis (NS5A inhibitors, DGAT1 inhibitors, glycosidase inhibitors, MTP inhibitors)


HCV Siklüsü




HCV ve T Lenfositler




HCV İnfeksiyonu



miRNA



HCV ve NK Hücreler




a

Presence of NK cells	Absence of NK cells
High-dose LCMV (5×10^6 PFU) Drives CD8⁺ T cell exhaustion in absence of CD4⁺ T cell help Viremia high (day 8) Pathology minimal (day 15) Survival LCMV-specific T cells: Frequency ↓↓ TNF-α IFN-γ ↓↓ Cytotoxicity ↓↓	Reduced viremia (day 8) Pathology ↑↑↑ (day 15) Death (58% mice) LCMV-specific T cells: Frequency ↑↑ TNF-α IFN-γ ↑↑ Cytotoxicity ↑↑
Medium-dose LCMV (5×10^5 PFU) Not sufficient for T cell exhaustion Viremia high (day 15) Pathology ↑↑ (day 15) Death (23% mice)	Virus clearance (day 8) No pathology (day 15) Survival
Low-dose LCMV (5×10^4 PFU) Virus clearance Pathology minimal (day 15) Survival	Virus clearance rapid (<day 7) Pathology minimal (day 15) Survival

a

Presence of NK cells	Absence of NK cells
High-dose LCMV (5×10^6 PFU) Drives CD8⁺ T cell exhaustion in absence of CD4⁺ T cell help Viremia high (day 8) Pathology minimal (day 15) Survival LCMV-specific T cells: Frequency ↓↓ TNF-α IFN-γ ↓↓ Cytotoxicity ↓↓	Reduced viremia (day 8) Pathology ↑↑↑ (day 15) Death (58% mice) LCMV-specific T cells: Frequency ↑↑ TNF-α IFN-γ ↑↑ Cytotoxicity ↑↑
Medium-dose LCMV (5×10^5 PFU) Not sufficient for T cell exhaustion Viremia high (day 15) Pathology ↑↑ (day 15) Death (23% mice)	Virus clearance (day 8) No pathology (day 15) Survival
Low-dose LCMV (5×10^4 PFU) Virus clearance Pathology minimal (day 15) Survival	Virus clearance rapid (<day 7) Pathology minimal (day 15) Survival


b




Kronik Karaciğer Hastalığında İlgili Kemokinlerin Rolü

Chemokine	Alternative name(s)	Main chemokine receptor(s)	Target cell(s)	Suggested involvement in liver disease
CCL1	I-309, TCA-3	CCR8	Monocytes/macrophages	Fibrosis
CCL2	MCP-1	CCR2	Monocytes/macrophages, HSCs	Initiation of inflammation, fibrosis, NAFLD/NASH
CCL3	MIP-1 α	CCR1, CCR5	NK, Th1, CD8 T	<u>HCV, HBV, NAFLD/NASH, fibrosis</u>
CCL4	MIP-1 β	CCR1, CCR5	NK, Th1, CD8 T	<u>HCV, HBV, NAFLD/NASH, fibrosis</u>
CCL5	RANTES	CCR1, CCR5	NK, Th1, CD8 T, HSCs	<u>HCV, HBV, NAFLD/NASH, fibrosis</u>
CCL17	TARC	CCR4	Treg	<u>HCV</u>
CCL19	ELC	CCR7	CD8 T, DCs	<u>HCV</u>
CCL20	MIP-3 α	CCR6	$\gamma\delta$ T, Th17, HSCs	Cholestatic, HCV, alcohol, fibrosis
CCL21	SLC	CCR7	CD8 T, DCs	<u>HCV, fibrosis</u>
CCL22	MDC	CCR4	Treg	<u>HCV</u>
CCL25	TECK	CCR9	Monocytes/macrophages, HSCs	Fibrosis
CXCL1	Gro- α	CXCR2	Neutrophils, monocytes	Initiation of inflammation, alcohol
CXCL2	Gro- β	CXCR2	Neutrophils, monocytes	Initiation of inflammation, alcohol
CXCL5	ENA-78	CXCR2	Neutrophils	Alcohol, fibrosis
CXCL6	GCP-2	CXCR1, CXCR2	Neutrophils, monocytes	alcohol
CXCL8	IL-8	CXCR1, CXCR2	Neutrophils, monocytes	Initiation of inflammation, alcohol, HBV
CXCL9	MIG	CXCR3	NK, Th1, Th17	<u>HCV, fibrosis</u>
CXCL10	IP-10	CXCR3	NK, Th1, Th17, HSCs	<u>Cholestatic, HCV, HBV, fibrosis</u>
CXCL11	I-TAC	CXCR3	NK, Th1, Th17	<u>HCV, fibrosis</u>
CXCL12	SDF-1	CXCR4, CXCR7	HSCs, LSECs, HCCs	Fibrosis, regeneration, HCC
CXCL13	BCA-1	CXCR5	B cells	<u>HCV</u>
CXCL16	SRPSOX	CXCR6	NKT cells	<u>HCV, fibrosis</u>
CX3CL1	Fractalkine, neurotactin	CX3CR1	Monocytes/macrophages	<u>HCV, fibrosis</u>


HCV ve Kemokinler




HCV ve Kemokinler




Fibrogenesis




Fibrosis resolution






FIBROGENESIS


RESOLUTION




HCV ve Yolaklar




HCV ve Lipid Damlaları




HCV Siklusu ve Doğal İmmünite




HCV




HCV Siklüsü ve Tedavi Hedefleri







HCV Klirensi




HCV ve IKK




HCV ve Kronikleşme Patogenezi



HCV ve Kronikleşme Patogenezi



HCV



Dinlediğiniz için teşekkür ederim.

Kaynaklar

- 1.Q J Med 2012; 105:109–113
- 2.*Physiol Genomics* 45: 1035–1048, 2013.
- 3.*Hepatobiliary Surg Nutr* 2013;2(1):37-39
- 4.*Frontiers in Physiology* 2014;5:212-220
- 5.*Gut* 2009;58:846–858
- 6.*Int. J. Mol. Sci.* 2014, 15, 9184-9208
- 7.*J Clin Invest.* 2011;121(1):25–27.
- 8.*Nature Cell Biology* 2007;9:837--850
- 9.*Nature Medicine* 2013;19:879-889
- 10.*Viruses* 2012, 4, 2485-2513
- 11.*Journal of Hepatology* 2014 vol. 61 j 660–671
- 12.*Antiviral Research* 96 (2012) 405–413
- 13.*Journal of Hepatology* 49 (2008) 396–406
- 14.*Cancer Letters* 286 (2009) 69–79
- 15.*Microbial Pathogenesis* 74 (2014) 59e62
- 16.*Biochimica et Biophysica Acta* 1809 (2011) 678–685
- 17.*J. Mol. Biol.* (2014) 426, 1198–1209